[go: up one dir, main page]

OA10362A - Protéines obèses (ob) recombinantes - Google Patents

Protéines obèses (ob) recombinantes Download PDF

Info

Publication number
OA10362A
OA10362A OA60824D OA60824D OA10362A OA 10362 A OA10362 A OA 10362A OA 60824 D OA60824 D OA 60824D OA 60824 D OA60824 D OA 60824D OA 10362 A OA10362 A OA 10362A
Authority
OA
OAPI
Prior art keywords
protein
human
murine
seq
obese
Prior art date
Application number
OA60824D
Other languages
English (en)
French (fr)
Inventor
Arthur Campfield
Rene Devos
Yves Guisez
Pascal Sebastian Bailon
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of OA10362A publication Critical patent/OA10362A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
OA60824D 1995-05-05 1996-05-03 Protéines obèses (ob) recombinantes OA10362A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43577795A 1995-05-05 1995-05-05
US48462995A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
OA10362A true OA10362A (fr) 2001-11-15

Family

ID=27030682

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60824D OA10362A (fr) 1995-05-05 1996-05-03 Protéines obèses (ob) recombinantes

Country Status (35)

Country Link
US (1) US6025325A (bg)
EP (1) EP0741187A2 (bg)
JP (1) JP3244627B2 (bg)
KR (1) KR100219970B1 (bg)
CN (1) CN1157290A (bg)
AR (1) AR003087A1 (bg)
AU (1) AU688210B2 (bg)
BG (1) BG62975B1 (bg)
BR (1) BR9602166A (bg)
CA (1) CA2175298A1 (bg)
CZ (1) CZ129796A3 (bg)
DE (1) DE741187T1 (bg)
ES (1) ES2093593T1 (bg)
GR (1) GR960300075T1 (bg)
HR (1) HRP960213A2 (bg)
HU (1) HU220093B (bg)
IL (1) IL118059A0 (bg)
IS (1) IS4343A (bg)
MA (1) MA23856A1 (bg)
MY (1) MY132189A (bg)
NO (1) NO961796L (bg)
NZ (1) NZ286466A (bg)
OA (1) OA10362A (bg)
PE (1) PE50897A1 (bg)
PL (1) PL186568B1 (bg)
RO (1) RO117177B1 (bg)
RU (1) RU96109211A (bg)
SG (1) SG49337A1 (bg)
SK (1) SK56996A3 (bg)
SV (1) SV1996000030A (bg)
TN (1) TNSN96066A1 (bg)
TR (1) TR199600357A2 (bg)
TW (1) TW464655B (bg)
UY (1) UY24219A1 (bg)
YU (1) YU26596A (bg)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
AU674500B2 (en) 1991-11-04 1997-01-02 Genetics Institute, Llc Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DK0733109T3 (da) 1993-12-07 2006-07-03 Genetics Inst Llc BMP-12, BMP-13 og seneinducerende præparater dermed
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
BR9612359A (pt) * 1995-12-27 1999-07-13 Genentech Inc Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) * 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
EP0877627A1 (en) * 1996-01-25 1998-11-18 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US7067472B1 (en) * 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US20030036629A1 (en) * 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
ES2225241T3 (es) 1999-10-15 2005-03-16 Genetics Institute, Llc Formulaciones de acido hialuronico para suministrar proteinas osteogenicas.
WO2001096565A2 (en) * 2000-06-16 2001-12-20 Asterion Limited Binding agents: chimeric ligand/receptor proteins
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
JP2005500280A (ja) 2001-06-01 2005-01-06 ワイエス 骨形成タンパク質(bmp)をコードする配列の全身投与のための組成物および方法
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
ES2350924T3 (es) 2001-10-22 2011-01-28 Amgen, Inc. Uso de leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento.
AU2003225277A1 (en) * 2002-05-02 2003-11-17 Robert Harris Lipid removal from the body
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE602004005477T2 (de) 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
ES2664822T3 (es) * 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
EP2326339A4 (en) * 2008-05-21 2012-06-20 Neurotez Inc METHOD FOR TREATING PROGRESSIVE COGNITIVE DISORDER IN CONNECTION WITH NEUROFIBRILLARY TANGLES
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ,インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
EP2667899A1 (en) 2011-01-26 2013-12-04 Novo Nordisk A/S Leptin derivatives
US12139555B2 (en) * 2019-12-03 2024-11-12 Rodan & Fields, Llc Peptides and compositions for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199337A (en) * 1978-10-06 1980-04-22 International Telephone And Telegraph Corporation Method of fabricating high strength optical preforms
US4666836A (en) * 1981-01-02 1987-05-19 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4643969A (en) * 1983-07-25 1987-02-17 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
US4757013A (en) * 1983-07-25 1988-07-12 The Research Foundation Of State University Of New York Cloning vehicles for polypeptide expression in microbial hosts
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU3329895A (en) * 1994-08-17 1996-03-07 Rockefeller University, The Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5861485A (en) * 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
WO1996023517A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
CA2223433C (en) * 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
BR9612359A (pt) * 1995-12-27 1999-07-13 Genentech Inc Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos

Also Published As

Publication number Publication date
GR960300075T1 (en) 1996-12-31
HU220093B (hu) 2001-10-28
EP0741187A2 (en) 1996-11-06
US6025325A (en) 2000-02-15
YU26596A (sh) 1999-03-04
BR9602166A (pt) 1998-01-13
AU5197896A (en) 1996-11-14
RO117177B1 (ro) 2001-11-30
NO961796L (no) 1996-11-06
MA23856A1 (fr) 1996-12-31
CZ129796A3 (en) 1997-01-15
ES2093593T1 (es) 1997-01-01
KR960041194A (ko) 1996-12-19
DE741187T1 (de) 1997-04-30
IS4343A (is) 1996-12-09
MX9601655A (es) 1997-07-31
MY132189A (en) 2007-09-28
BG100558A (bg) 1997-03-31
UY24219A1 (es) 2001-03-16
PL314051A1 (en) 1996-11-12
HRP960213A2 (en) 1997-10-31
AU688210B2 (en) 1998-03-05
JPH093098A (ja) 1997-01-07
BG62975B1 (bg) 2000-12-29
SG49337A1 (en) 1998-05-18
CA2175298A1 (en) 1996-11-06
TR199600357A2 (tr) 1996-11-21
SV1996000030A (es) 1999-01-14
HUP9601120A3 (en) 1999-07-28
HUP9601120A2 (en) 1996-11-28
SK56996A3 (en) 1997-04-09
JP3244627B2 (ja) 2002-01-07
AR003087A1 (es) 1998-07-08
PE50897A1 (es) 1997-12-19
CN1157290A (zh) 1997-08-20
PL186568B1 (pl) 2004-01-30
RU96109211A (ru) 1998-10-27
HU9601120D0 (en) 1996-06-28
TW464655B (en) 2001-11-21
NZ286466A (en) 1998-03-25
IL118059A0 (en) 1996-08-04
EP0741187A3 (bg) 1996-12-11
TNSN96066A1 (fr) 2005-03-15
NO961796D0 (no) 1996-05-03
KR100219970B1 (ko) 1999-10-01

Similar Documents

Publication Publication Date Title
OA10362A (fr) Protéines obèses (ob) recombinantes
EP1135168B1 (fr) Vecteurs peptidiques de substances a travers la barriere hemato-encephalique
HUT70309A (en) Production and use of multimeric hemoglobins
HU229068B1 (hu) Urát oxidáz változatok és alkalmazásuk
JP2017518298A (ja) インスリン及びglp−1/グルカゴン二重アゴニストを含む糖尿病治療用組成物
CA2184841C (fr) Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf)
WO1993015211A1 (fr) Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant
HU229626B1 (hu) Urát oxidáz változat és alkalmazása
JP2002531050A (ja) 抗メチオニンおよび抗ホモシステイン化学療法におけるメチオニナーゼの使用
EP0537166B1 (fr) Polypeptides hydrosolubles ayant une haute affinite pour les interferons alpha et beta
CN112218644A (zh) 人类犬尿氨酸酶及其用途
WO1996014415A1 (fr) Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
EP1397161B1 (fr) Composes constitues d'une molecule analgesique liee a un vecteur
FR2572936A1 (fr) Nouveau lymphokine et anticorps monoclonal specifique de ce lymphokine, leurs production et utilisations
FR2657881A1 (fr) Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
WO1995025803A1 (fr) ADENOVIRUS RECOMBINANTS CODANT POUR LE FACTEUR DE CROISSANCE DES FIBROBLASTES ACIDES (aFGF)
AU728834B3 (en) Recombinant proteins
EP0139555B1 (fr) Nouveau peptide de synthèse, son procédé de préparation et médicaments le contenant
AU5358399A (en) Proteins
MXPA96001655A (en) Proteins (ob) obesas recommend
WO1994019462A1 (fr) Facteurs de croissance de la famille de l'harp, procede d'obtention et applications
CA2166298A1 (fr) Famille de peptides appeles xenoxines
FR3147278A1 (fr) Polypeptides de liaison au tnfr2 et procedes d'utilisation
CA2124948A1 (fr) Cytokine antagoniste de l'ifn-gamma
EP1244690B1 (fr) Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent